Lonza sells its Capsules & Health Ingredients unit for CHF 2.3B to Lone Star Funds, completing its shift to a pure-play CDMO. Proceeds will fuel growth, acquisitions, and share buybacks.
Novo Nordisk is gaining momentum in India’s obesity drug market as semaglutide sales rise following price cuts and wider availability. The move is helping the company narrow the lead held by Eli Lilly’s tirzepatide in the fast-growing GLP-1 segment.
Alembic Pharmaceuticals achieves a milestone with the prescription-based sale of Pivya, a first-line oral antibiotic for UTI treatment, marking a key growth in global markets.
A new study shows laser treatment before immunotherapy could help patients with aggressive brain tumors live longer.
The Medicity has launched a public awareness campaign to shift the focus from seasonal concern over air pollution to continuous monitoring and prevention of chronic respiratory diseases (CRDs).
.jpeg)
MedGenome invests in Medcare to strengthen India’s integrated diagnostics ecosystem, combining advanced imaging, pathology, and genomics for better early disease detection.
Zydus Lifesciences has received final USFDA approval for its Ivermectin Tablets 3 mg and Dapsone Tablets 25 mg and 100 mg, further expanding its global pharmaceutical footprint.
Eli Lilly and Company reported that its investigational oral GLP-1 receptor agonist, orforglipron, achieved superior blood sugar control and weight loss compared with oral semaglutide in a head-to-head phase 3 trial in adults with type 2 diabet...
Boehringer Ingelheim has received FDA approval for its drug Ofev as a first-line treatment for non-small cell lung cancer. The approval offers a new option for patients with metastatic NSCLC, combining Ofev with chemotherapy for better outcomes.
.png)
Lupin Limited has announced FDA approval for its Brivaracetam Oral Solution 10 mg/mL, a bioequivalent of UCB’s Briviact, designed to treat partial-onset seizures in patients 1 month and older. The launch is now underway in the U.S.
.jpg)
, CDSCO.jpg)